Scarica l'app Stockscreener
46.34
0.02%
-0.010
Pre-mercato:
46.40
0.06
+0.13%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché BMY Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Bristol Myers Squibb Co Borsa (BMY) Ultime notizie
Canandaigua National Bank & Trust Co. Has $1.47 Million Position in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers to sell 60% stake in China joint venture By Reuters - Investing.com
Bristol Myers to sell 60% stake in China joint venture - Reuters
Bristol Myers Squibb To Exit Historic China Joint Venture - Finimize
Bristol Myers Squibb (NYSE:BMY) Stock Unloaded Rep. Julie Johnson - MarketBeat
What Does Wall Street Think About Bristol-Myers Squibb (BMY)? - MSN
Bristol-Myers Squibb Company (BMY)-BioNTech Lung Cancer Therapy Shows 76% Tumor Reduction - uk.finance.yahoo.com
Bristol Myers Sells Out of First US Drugs Joint Venture in China - Yicai Global
2025 Annual Review of the 2024 Pharmaceutical Drug Development Market Featuring Pfizer, Merck, Novar - PharmiWeb.com
Gap Down: Is Bristol Myers Squibb Company Equity Right stock good for income investorsWeekly Trading Summary & Weekly Market Pulse Alerts - خودرو بانک
Bristol-Myers Squibb: Hold Rating Amid Slower Cobenfy Launch and Fair Valuation - TipRanks
Aug Wrap: Will Bristol Myers Squibb Company Equity Right stock hit new highs in YEARWall Street Watch & AI Enhanced Trade Execution Alerts - خودرو بانک
Biokin/BMS, Genfleet/Verastem’s Drug Candidates Impress At WCLC - insights.citeline.com
Ascent Group LLC Buys 8,721 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Promising Lung Cancer Trial Results Could Be a Game Changer for Bristol-Myers Squibb (BMY) - simplywall.st
UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC Has $1.38 Billion Position in Bristol Myers Squibb Company $BMY - MarketBeat
Flputnam Lifts Stake in Bristol-Myers Squibb Company (BMY) by 52% - MSN
BMY-BioNTech Partnership: A Potential Catalyst for Long-Term Gains? - Yahoo Finance
Bristol Myers Squibb Company (BMY) is Attracting Investor Attention: Here is What You Should Know - Yahoo Finance
Stance Capital LLC Purchases 39,165 Shares of Bristol Myers Squibb Company $BMY - MarketBeat
Graham Capital Management L.P. Invests $568,000 in Bristol Myers Squibb Company $BMY - MarketBeat
BMO Capital Maintains a Hold on Bristol-Myers Squibb Company (BMY) - Insider Monkey
Bristol Myers Squibb, BioNTech Announce Positive Interim Data from Phase 2 Trial of Pumitamig in Lung Cancer - Insider Monkey
Bipolar Disorder Treatment Pipeline Shows Strong Momentum as 20+ Pharma Companies in the Race | DelveInsight - GlobeNewswire Inc.
October 31st Options Now Available For Bristol Myers Squibb (BMY) - Nasdaq
Bristol Myers Loses 19.2% in Six Months: Buy, Sell or Hold? - Yahoo Finance
Bristol-Myers Squibb (BMY): Assessing Valuation After New Pipeline Updates and Growth Strategy Reveal - Yahoo Finance
Bristol Myers Squibb Company $BMY Shares Acquired by Bayforest Capital Ltd - MarketBeat
United Services Automobile Association Has $12.60 Million Stake in Bristol Myers Squibb Company $BMY - MarketBeat
Bristol Myers Squibb (BMY) Outperforms Broader Market: What You Need to Know - Yahoo Finance
BioNTech and Bristol-Myers Squibb Partner to Advance Cancer Therapy - MSN
BMS, BioNTech Post Geographically Consistent Mid-Stage PD-L1/VEGF Data in SCLC - BioSpace
WCLC25: BioNTech, BMS tout second readout for PD-L1/VEGF-A in SCLC - FirstWord Pharma
BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy - Benzinga
BioNTech and Bristol Myers Squibb amend partnership for BNT327 with $1.5 billion upfront payment - Investing.com Canada
First Disclosure of Global Interim Phase 2 Data for BioNTech and Bristol Myers Squibb PD-L1xVEGF-A Bispecific Antibody Pumitamig (BNT327/BMS986545) in Patients with Extensive-Stage Small Cell Lung Cancer Shows Encouraging Antitumor Activity - The Manila Times
BioNTech, Bristol Myers present interim data from a Phase 2 pumitamig trial - TipRanks
BioNTech and Bristol Myers Squibb Announce Encouraging Phase 2 Data for Pumitamig Plus Chemotherapy in Extensive-Stage Small Cell Lung Cancer - Quiver Quantitative
BioNTech, Bristol Myers' immunotherapy shows encouraging tumour shrinkage in Phase II trial - Reuters
BioNTech, BMS tout first global data for PD-L1xVEGF bispecific in small cell lung cancer, set phase 3 dose - Fierce Biotech
Bristol-Myers Squibb at Morgan Stanley Conference: Strategic Insights - Investing.com
Hold Recommendation for Bristol-Myers Squibb Due to Cobenfy’s Modest Growth and Revenue Projections - TipRanks
Bristol-Myers Squibb: Why Q2 Results Signal A Turning Point (NYSE:BMY) - Seeking Alpha
Bristol-Myers Squibb: Growth Portfolio Surpasses Legacy, Driving Oncology And Immunology Leadership (NYSE:BMY) - Seeking Alpha
Bristol Myers Squibb Company $BMY Shares Purchased by Baird Financial Group Inc. - MarketBeat
What is Bristol Myers Squibb Company s debt to equity ratioWeekly Earnings Recap & Free Accurate Trade Setup Notifications - خودرو بانک
Is Bristol-Myers Squibb (BMY) a Value Trap or a Sleeping Giant in Biopharma? - AInvest
Short interest data insights for Bristol Myers Squibb Company Equity RightJuly 2025 Catalysts & High Accuracy Swing Trade Signals - Newser
Using data tools to time your Bristol Myers Squibb Company exitGap Down & Fast Entry and Exit Trade Plans - Newser
Bravehart, a stealthy startup, looks to China to challenge Bristol Myers heart drug - BioPharma Dive
Independent research - Bristol Myers Squibb
0.51%
0.29%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):